
--- Page 1 ---
510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
ASSAY ONLY
I Background Information:
A 510(k) Number
K201630
B Applicant
Assure Tech (Hangzhou) Co., Ltd.
C Proprietary and Established Names
AssureTech DOA Dipstick Screen Panel Tests, AssureTech DOA Integrated Cup Tests
D Regulatory Information
Product Regulation
Classification Panel
Code(s) Section
21 CFR 862.3650 - Opiate Test TX - Clinical
DJG Class II
System Toxicology
21 CFR 862.3100 - TX - Clinical
DKZ Class II
Amphetamine test system Toxicology
21 CFR 862.3870 - Cannabinoid TX - Clinical
LDJ Class II
test system Toxicology
21 CFR 862.3250 - Cocaine and TX - Clinical
DIO Class II
cocaine metabolite test system Toxicology
21 CFR 862.3610 - TX - Clinical
LAF Class II
Methamphetamine test system Toxicology
21 CFR 862.3170 - TX - Clinical
JXM Class II
Benzodiazepine test system Toxicology
21 CFR 862.3150 - Barbiturate TX - Clinical
DIS Class II
test system Toxicology
LCM Unclassified
21 CFR 862.3620 - Methadone TX - Clinical
DJR Class II
test system Toxicology
21 CFR 862.3910 - Tricyclic TX - Clinical
LFG Class II
antidepressant drugs test system Toxicology
21 CFR 862.3700 - TX - Clinical
JXN Class II
Propoxyphene test system Toxicology

[Table 1 on page 1]
	Product		Classification		Regulation		Panel
	Code(s)				Section		
DJG			Class II	21 CFR 862.3650 - Opiate Test
System			TX - Clinical
Toxicology
DKZ			Class II	21 CFR 862.3100 -
Amphetamine test system			TX - Clinical
Toxicology
LDJ			Class II	21 CFR 862.3870 - Cannabinoid
test system			TX - Clinical
Toxicology
DIO			Class II	21 CFR 862.3250 - Cocaine and
cocaine metabolite test system			TX - Clinical
Toxicology
LAF			Class II	21 CFR 862.3610 -
Methamphetamine test system			TX - Clinical
Toxicology
JXM			Class II	21 CFR 862.3170 -
Benzodiazepine test system			TX - Clinical
Toxicology
DIS			Class II	21 CFR 862.3150 - Barbiturate
test system			TX - Clinical
Toxicology
LCM			Unclassified				
DJR			Class II	21 CFR 862.3620 - Methadone
test system			TX - Clinical
Toxicology
LFG			Class II	21 CFR 862.3910 - Tricyclic
antidepressant drugs test system			TX - Clinical
Toxicology
JXN			Class II	21 CFR 862.3700 -
Propoxyphene test system			TX - Clinical
Toxicology

--- Page 2 ---
II Submission/Device Overview:
A Purpose for Submission:
New device
B Measurand:
6-Monoacetylmorphine, Amphetamine, Oxazepam, Cocaine, Marijuana, Methamphetamine,
Morphine, Oxycodone, Secobarbital, Buprenorphine, Methylenedioxy-methamphetamine,
Phencyclidine, Methadone, EDDP, Nortriptyline and d-Propoxyphene
C Type of Test:
Qualitative lateral flow immunoassay
III Intended Use/Indications for Use:
A Intended Use(s):
See Indications for Use below.
B Indication(s) for Use:
AssureTech DOA Dipstick Screen Panel Tests are competitive binding, lateral flow
immunochromatographic assays for qualitative and simultaneous detection of 6-
Monoacetylmorphine, Amphetamine, Oxazepam, Cocaine, Marijuana, Methamphetamine,
Morphine, Oxycodone, Secobarbital, Buprenorphine, Methylenedioxy-methamphetamine,
Phencyclidine, Methadone, EDDP, Nortriptyline and d-Propoxyphene in human urine at the
cutoff concentrations of:
Drug(Identifier) Cut-off level
6-Monoacetylmorphine 10 ng/mL
Amphetamine 500 ng/mL
Oxazepam 300 ng/mL
Cocaine 150 ng/mL
Marijuana 20 ng/mL
Methamphetamine 500 ng/mL
Morphine 300 ng/mL
Oxycodone 100 ng/mL
Secobarbital 300 ng/mL
Buprenorphine 10 ng/mL
Methylenedioxy-methamphetamine 500 ng/mL
Phencyclidine 25 ng/mL
Methadone 300 ng/mL
EDDP 300 ng/mL
Nortriptyline 1000 ng/mL
d-Propoxyphene 300 ng/mL

--- Page 3 ---
Configuration of the AssureTech DOA Dipstick Screen Panel Tests can consist of any
combination of the above listed drug analytes.
The test may yield positive results for the prescription drugs Buprenorphine, Nortriptyline,
Oxazepam, Secobarbital, Propoxyphene and Oxycodone when taken at or above prescribed
doses. It is not intended to distinguish between prescription use or abuse of these drugs. Clinical
consideration and professional judgment should be exercised with any drug of abuse test result,
particularly when the preliminary result is positive. The test provides only preliminary test
results. A more specific alternative chemical method must be used in order to obtain a confirmed
analytical result. GC/MS or LC/MS is the preferred confirmatory method.
For in vitro diagnostic use only.
AssureTech DOA Integrated Cup Tests are competitive binding, lateral flow
immunochromatographic assays for qualitative and simultaneous detection of 6-
Monoacetylmorphine, Amphetamine, Oxazepam, Cocaine, Marijuana, Methamphetamine,
Morphine, Oxycodone, Secobarbital, Buprenorphine, Methylenedioxy-methamphetamine,
Phencyclidine, Methadone, EDDP, Nortriptyline and d-Propoxyphene in human urine at the
cutoff concentrations of:
Drug(Identifier) Cut-off level
6-Monoacetylmorphine 10 ng/mL
Amphetamine 500 ng/mL
Oxazepam 300 ng/mL
Cocaine 150 ng/mL
Marijuana 20 ng/mL
Methamphetamine 500 ng/mL
Morphine 300 ng/mL
Oxycodone 100 ng/mL
Secobarbital 300 ng/mL
Buprenorphine 10 ng/mL
Methylenedioxy-methamphetamine 500 ng/mL
Phencyclidine 25 ng/mL
Methadone 300 ng/mL
EDDP 300 ng/mL
Nortriptyline 1000 ng/mL
d-Propoxyphene 300 ng/mL
Configuration of the AssureTech DOA Integrated Cup Tests can consist of any combination of
the above listed drug analytes.
The test may yield positive results for the prescription drugs Buprenorphine, Nortriptyline,
Oxazepam, Secobarbital, Propoxyphene and Oxycodone when taken at or above prescribed
doses. It is not intended to distinguish between prescription use or abuse of these drugs. Clinical
consideration and professional judgment should be exercised with any drug of abuse test result,
particularly when the preliminary result is positive. The test provides only preliminary test

--- Page 4 ---
results. A more specific alternative chemical method must be used in order to obtain a confirmed
analytical result. GC/MS or LC/MS is the preferred confirmatory method.
For in vitro diagnostic use only.
C Special Conditions for Use Statement(s):
Rx - For Prescription Use Only
D Special Instrument Requirements:
Not applicable
IV Device/System Characteristics:
A Device Description:
The device is available in a cup and dip card format. With the cup format, the test strips are
integrated into the cup provided and the urine sample is collected directly into the cup containing
the strips. With the dip card format, the urine is collected into a clean, dry container (not
included) and the dip card is dipped into the urine that has been collected. Both formats use the
same test strips.
B Principle of Operation:
Immunochromatographic assays of AssureTech DOA Dipstick Screen Panel and the DOA
Integrated Cup Tests use a lateral flow, one step system for the qualitative detection of 6-
Monoacetylmorphine, Amphetamine, Oxazepam, Cocaine, Marijuana, Methamphetamine,
Morphine, Oxycodone, Secobarbital, Buprenorphine, Methylenedioxy-methamphetamine,
Phencyclidine, Methadone, EDDP, Nortriptyline and d-Propoxyphene (target analyte) in human
urine. Each assay uses a monoclonal antibody-dye conjugate against drugs with gold chloride
and fixed drug-protein conjugates and anti-mouse IgG polyclonal antibody in membranes. When
the absorb end is immersed into the urine specimen, the urine is absorbed into the device by
capillary action, mixes with the antibody-dye conjugate, and flows across the pre-coated
membrane. When sample drug levels are zero or below the target cut-off (the detection
sensitivity of the test), antibody-dye conjugate binds to the drug-protein conjugate immobilized
in the Test Region (T) of the device. This produces a colored Test line that, regardless of its
intensity, indicates a negative result. When sample drug levels are at or above the target Cut-Off,
the free drug in the sample binds to the antibody-dye conjugate preventing the antibody-dye
conjugate from binding to the drug-protein conjugate immobilized in the Test Region (T) of the
device. This prevents the development of a distinct colored band in the test region, indicating a
potentially positive result.
To serve as a procedure control, a colored line will appear at the Control Region (C), if the test
has been performed properly because of the antibody-dye conjugate binding to anti-mouse IgG
immobilized in the Control Region (C) of the device.

--- Page 5 ---
V Substantial Equivalence Information:
A Predicate Device Name(s):
AssureTech Panel Dip Tests, AssureTech Quick Cup Tests, ATTEST Drug Screen Cup,
ATTEST Drug Screen Dip Card
B Predicate 510(k) Number(s):
K181768, K182123
C Comparison with Predicate(s):
Device & Predicate
K201630 K181768
Device(s):
AssureTech DOA
AssureTech Panel Dip
Dipstick Screen Panel
Device Trade Name Tests, AssureTech
Tests, AssureTech
Quick Cup Tests
DOA Integrated Cup
Tests
General Device
Characteristic Similarities
For the qualitative
detection of
Amphetamine,
Oxazepam, Cocaine,
Marijuana,
Methamphetamine,
Morphine, Oxycodone,
Intended Use/Indications Same, with the addition Secobarbital,
For Use of 6-MAM Buprenorphine,
Methylenedioxy-
methamphetamine,
Phencyclidine,
Methadone, EDDP,
Nortriptyline and
Propoxyphene in human
urine.
General Device
Characteristic Differences
Number of analytes 16 15
Cutoff (THC) 20 ng/mL 50 ng/mL

[Table 1 on page 5]
	Device & Predicate		K201630	K181768
	Device(s):			
Device Trade Name			AssureTech DOA
Dipstick Screen Panel
Tests, AssureTech
DOA Integrated Cup
Tests	AssureTech Panel Dip
Tests, AssureTech
Quick Cup Tests
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Same, with the addition
of 6-MAM	For the qualitative
detection of
Amphetamine,
Oxazepam, Cocaine,
Marijuana,
Methamphetamine,
Morphine, Oxycodone,
Secobarbital,
Buprenorphine,
Methylenedioxy-
methamphetamine,
Phencyclidine,
Methadone, EDDP,
Nortriptyline and
Propoxyphene in human
urine.
	General Device			
	Characteristic Differences			
Number of analytes			16	15
Cutoff (THC)			20 ng/mL	50 ng/mL

--- Page 6 ---
Device & Predicate
K201630 K182123
Device(s):
AssureTech DOA
ATTEST Drug Screen
Dipstick Screen Panel
Device Trade Name Cup, ATTEST Drug
Tests, AssureTech
Screen Dip Card
DOA Integrated Cup
Tests
General Device
Characteristic Similarities
For the qualitative
detection of 6-
Acetylmorphine, d-
Amphetamine,
Benzoylecgonine,
Buprenorphine, EDDP,
d/l-Methadone, d-
Intended Use/Indications Methamphetamine, d/l-
Same, different analytes
For Use Methylenedioxymetham
phetamine, Morphine,
Nortriptyline,
Oxazepam, Oxycodone,
Phencyclidine, d-
Propoxyphene,
Secobarbital and THC-
COOH in human urine
General Device
Characteristic Differences
Number of analytes 16 20
VI Standards/Guidance Documents Referenced:
None referenced.
VII Performance Characteristics (if/when applicable):
A Analytical Performance:
1. Precision/Reproducibility:
Nine sample pools were prepared by spiking target drugs in drug-free urine samples. Each
percentage is % cut-off corresponding to each target drug in each of the nine drug mix samples.
The number under drug abbreviation is cut-off value of the drug.
Each sample pools were further aliquoted into 180 individual containers (total 1620 aliquots, 90
aliquots per spiked sample for each test format). All aliquots were blinded labeled by the person
who prepared the samples and didn’t take part in the sample testing. Drug concentrations of the

[Table 1 on page 6]
	Device & Predicate		K201630	K182123
	Device(s):			
Device Trade Name			AssureTech DOA
Dipstick Screen Panel
Tests, AssureTech
DOA Integrated Cup
Tests	ATTEST Drug Screen
Cup, ATTEST Drug
Screen Dip Card
	General Device			
	Characteristic Similarities			
Intended Use/Indications
For Use			Same, different analytes	For the qualitative
detection of 6-
Acetylmorphine, d-
Amphetamine,
Benzoylecgonine,
Buprenorphine, EDDP,
d/l-Methadone, d-
Methamphetamine, d/l-
Methylenedioxymetham
phetamine, Morphine,
Nortriptyline,
Oxazepam, Oxycodone,
Phencyclidine, d-
Propoxyphene,
Secobarbital and THC-
COOH in human urine
	General Device			
	Characteristic Differences			
Number of analytes			16	20

--- Page 7 ---
sample pools were confirmed by LC/MS/MS. These concentrations were blinded to test
operators.
This was a multi-center study to validate the cutoff and precision of the AssureTech DOA
Dipstick Screen Screen Panel Tests and the AssureTech DOA Integrated Cup Tests. The three
sites represent the intended use settings of the product. Each study site had one test operator for
each format to test these samples over a 10-day period. Each operator tested and interpreted 270
specimens over the course of ten days (27 specimens per day, 3 lots × 9 concentrations). Each
operator could only test one device format, i.e., the person who tested the cup did not test the
panel dip.
Results are summarized below:
AssureTech DOA Integrated Cup Tests
CUP 6-MAM AMP BAR
Drug conc
as % of Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 24+/6- 23+/7- 23+/7- 23+/7- 24+/6- 26+/4- 28+/2- 26+/4- 28+/2-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
BUP BZO COC
Drug conc
as % of Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 28+/2- 27+/3- 27+/3- 28+/2- 28+/2- 29+/1- 23+/7- 26+/4- 24+/6-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-

[Table 1 on page 7]
CUP	6-MAM									AMP									BAR								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		24+/6-			23+/7-			23+/7-			23+/7-			24+/6-			26+/4-			28+/2-			26+/4-			28+/2-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

[Table 2 on page 7]
	BUP									BZO									COC								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		28+/2-			27+/3-			27+/3-			28+/2-			28+/2-			29+/1-			23+/7-			26+/4-			24+/6-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

--- Page 8 ---
EDDP MDMA MET
Drug conc
as % of Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 24+/6- 24+/6- 25+/5- 23+/7- 22+/8- 22+/8- 23+/7- 27+/3- 23+/7-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
MOR MTD OXY
Drug conc
as % of Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 22+/8- 24+/6- 23+/7- 26+/4- 27+/3- 27+/3- 27+/3- 28+/2- 28+/2-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
PCP PPX TCA
Drug conc
as % of Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 25+/5- 25+/5- 24+/6- 25+/5- 27+/3- 25+/5- 24+/6- 25+/5- 23+/7-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-

[Table 1 on page 8]
	EDDP									MDMA									MET								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		24+/6-			24+/6-			25+/5-			23+/7-			22+/8-			22+/8-			23+/7-			27+/3-			23+/7-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

[Table 2 on page 8]
	MOR									MTD									OXY								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		22+/8-			24+/6-			23+/7-			26+/4-			27+/3-			27+/3-			27+/3-			28+/2-			28+/2-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

[Table 3 on page 8]
	PCP									PPX									TCA								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		25+/5-			25+/5-			24+/6-			25+/5-			27+/3-			25+/5-			24+/6-			25+/5-			23+/7-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

--- Page 9 ---
THC
Drug conc
as % of Lot 1 Lot 2 Lot 3
cutoff
-100% 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+
cutoff
23+/7- 24+/6- 24+/6-
+25% 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0-
AssureTech DOA Dipstick Screen Panel Tests
CARD 6-MAM AMP BAR
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 24+/6 23+/7- 25+/5- 23+/7- 23+/7- 27+/3- 27+/3- 27+/3- 26+/4-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
BUP BZO COC
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 26+/4- 26+/4- 28+/2- 28+/2- 28+/2- 27+/3- 22+/8- 25+/5- 23+/7-
+25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-

[Table 1 on page 9]
	THC								
Drug conc
as % of
cutoff	Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+		
cutoff									
		23+/7-			24+/6-			24+/6-	
+25%	30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-		

[Table 2 on page 9]
CARD	6-MAM									AMP									BAR								
Drug
conc as
% of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3			Lot 1			Lot 2			Lot 3		
-100%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-75%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-50%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
-25%	30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+			30-/0+		
cutoff		24+/6			23+/7-			25+/5-			23+/7-			23+/7-			27+/3-			27+/3-			27+/3-			26+/4-	
+25%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+50%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+75%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		
+100%	30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-			30+/0-		

[Table 3 on page 9]
	BUP									BZO			COC		
Drug
conc as
% of
cutoff	Lot 1			Lot 2			Lot 3			Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
-100%	30-/0+			30-/0+			30-/0+			30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-75%	30-/0+			30-/0+			30-/0+			30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-50%	30-/0+			30-/0+			30-/0+			30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-25%	30-/0+			30-/0+			30-/0+			30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
cutoff		26+/4-			26+/4-			28+/2-		28+/2-	28+/2-	27+/3-	22+/8-	25+/5-	23+/7-
+25%	30+/0-			30+/0-			30+/0-			30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-

--- Page 10 ---
BUP BZO COC
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
+50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
EDDP MDMA BZO
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 24+/6- 24+/6- 24+/6- 24+/6- 24+/6- 22+/8- 25+/5 25+/5- 24+/6-
25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
MOR MTD OXY
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 23+/7- 24+/6- 25+/5- 27+/3- 26+/4- 26+/4- 28+/2- 27+/3- 28+/2-
25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-

[Table 1 on page 10]
	BUP			BZO			COC		
Drug
conc as
% of
cutoff	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
+50%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+75%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+100%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-

[Table 2 on page 10]
	EDDP			MDMA					
Drug
conc as
% of
cutoff	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
-100%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-75%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-50%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-25%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
cutoff	24+/6-	24+/6-	24+/6-	24+/6-	24+/6-	22+/8-	25+/5	25+/5-	24+/6-
25%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
50%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
75%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
100%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-

[Table 3 on page 10]
	MOR			MTD			OXY		
Drug
conc as
% of
cutoff	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
-100%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-75%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-50%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-25%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
cutoff	23+/7-	24+/6-	25+/5-	27+/3-	26+/4-	26+/4-	28+/2-	27+/3-	28+/2-
25%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
50%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+75%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+100%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-

--- Page 11 ---
PCP PPX TCA
Drug
conc as
Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3 Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+ 30-/0+
cutoff 25+/5- 25+/5- 24+/6- 25+/5- 25+/5- 26+/4- 23+/7- 23+/7- 24+/6-
25% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
50% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0- 30+/0-
THC
Drug
conc as
Lot 1 Lot 2 Lot 3
% of
cutoff
-100% 30-/0+ 30-/0+ 30-/0+
-75% 30-/0+ 30-/0+ 30-/0+
-50% 30-/0+ 30-/0+ 30-/0+
-25% 30-/0+ 30-/0+ 30-/0+
cutoff 24+/6- 22+/8- 22+/8-
25% 30+/0- 30+/0- 30+/0-
50% 30+/0- 30+/0- 30+/0-
+75% 30+/0- 30+/0- 30+/0-
+100% 30+/0- 30+/0- 30+/0-
2. Linearity:
Not applicable, these devices are intended for qualitative use only.
3. Analytical Specificity/Interference:
The sponsor performed specificity and cross-reactivity studies for the 6-Acetylmorphine (6-
MAM) and THC strips only. Please refer to k181768 for the specificity and cross-reactivity
performance for the remaining assays.
The sponsor performed studies to evaluate whether compounds structurally related to 6-
MAM and THC cross-react with the assays. The study used three lots and the testing was
performed by trained professionals by following the instructions in the package insert.
Results are summarized below:

[Table 1 on page 11]
	PCP			PPX			TCA		
Drug
conc as
% of
cutoff	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3	Lot 1	Lot 2	Lot 3
-100%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-75%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-50%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
-25%	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+	30-/0+
cutoff	25+/5-	25+/5-	24+/6-	25+/5-	25+/5-	26+/4-	23+/7-	23+/7-	24+/6-
25%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
50%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+75%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-
+100%	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-	30+/0-

[Table 2 on page 11]
	THC		
Drug
conc as
% of
cutoff	Lot 1	Lot 2	Lot 3
-100%	30-/0+	30-/0+	30-/0+
-75%	30-/0+	30-/0+	30-/0+
-50%	30-/0+	30-/0+	30-/0+
-25%	30-/0+	30-/0+	30-/0+
cutoff	24+/6-	22+/8-	22+/8-
25%	30+/0-	30+/0-	30+/0-
50%	30+/0-	30+/0-	30+/0-
+75%	30+/0-	30+/0-	30+/0-
+100%	30+/0-	30+/0-	30+/0-

--- Page 12 ---
6-acetylmorphine Result % Cross-Reactivity
(Cut-off=10 ng/mL) Positive at (ng/mL)
6-acetylmorphine 10 100%
Acetylcodeine >10000 <0.1%
Buprenorphine >10000 <0.1%
Codeine >10000 <0.1%
Diacetylmorphine 1000 1%
Dihydrocodeine >10000 <0.1%
Ethylmorphine >10000 <0.1%
Hydrocodone >10000 <0.1%
Hydromorphone 5000 0.2%
Morphine 10000 0.1%
Morphine-3- >10000 <0.1%
glucuronide
Nalorphine 5000 0.2%
Thebaine >20000 <0.05%
Dextromethorphan >100,000 <0.01%
Heroin 100,000 0.01%
Imipramine >100,000 <0.01%
LAAM >100,000 <0.01%
(Levacetylmethadol)
Levorphanol >100,000 <0.01%
Meperidine >100,000 <0.01%
Methadone >100,000 <0.01%
Mitragynine (kratom) >20,000 <0.05%
Morphine 6-D- >100,000 <0.01%
glucuronide
Naloxone >100,000 <0.01%
Naltrexone >100,000 <0.01%
Naproxen >100,000 <0.01%
Norbuprenorphine >10,000 <0.1%
Norbuprenorphine >100,000 <0.01%
glucuronide
Norcodeine >100,000 <0.01%
Norhydrocodone >100,000 <0.01%
Normorphine >100,000 <0.01%
Noroxycodone >100,000 <0.01%
Noroxymorphone >100,000 <0.01%
Norpropoxyphene >100,000 <0.01%
Oxycodone >100,000 <0.01%
Oxymorphone >100,000 <0.01%

[Table 1 on page 12]
6-acetylmorphine
(Cut-off=10 ng/mL)	Result
Positive at (ng/mL)	% Cross-Reactivity
6-acetylmorphine	10	100%
Acetylcodeine	>10000	<0.1%
Buprenorphine	>10000	<0.1%
Codeine	>10000	<0.1%
Diacetylmorphine	1000	1%
Dihydrocodeine	>10000	<0.1%
Ethylmorphine	>10000	<0.1%
Hydrocodone	>10000	<0.1%
Hydromorphone	5000	0.2%
Morphine	10000	0.1%
Morphine-3-
glucuronide	>10000	<0.1%
Nalorphine	5000	0.2%
Thebaine	>20000	<0.05%
Dextromethorphan	>100,000	<0.01%
Heroin	100,000	0.01%
Imipramine	>100,000	<0.01%
LAAM
(Levacetylmethadol)	>100,000	<0.01%
Levorphanol	>100,000	<0.01%
Meperidine	>100,000	<0.01%
Methadone	>100,000	<0.01%
Mitragynine (kratom)	>20,000	<0.05%
Morphine 6-D-
glucuronide	>100,000	<0.01%
Naloxone	>100,000	<0.01%
Naltrexone	>100,000	<0.01%
Naproxen	>100,000	<0.01%
Norbuprenorphine	>10,000	<0.1%
Norbuprenorphine
glucuronide	>100,000	<0.01%
Norcodeine	>100,000	<0.01%
Norhydrocodone	>100,000	<0.01%
Normorphine	>100,000	<0.01%
Noroxycodone	>100,000	<0.01%
Noroxymorphone	>100,000	<0.01%
Norpropoxyphene	>100,000	<0.01%
Oxycodone	>100,000	<0.01%
Oxymorphone	>100,000	<0.01%

--- Page 13 ---
6-acetylmorphine Result % Cross-Reactivity
(Cut-off=10 ng/mL) Positive at (ng/mL)
Oxymorphone-3β-D- >100,000 <0.01%
glucuronide
Tapentadol HCl >100,000 <0.01%
Tramadol >100,000 <0.01%
Marijuana Result % Cross-
(Cut-off=20 ng/mL) Positive at Reactivity
(ng/mL)
11-nor-D9-THC-9 COOH 20 100%
11-nor-D8-THC-9 COOH 20 100%
Δ8-Tetrahydrocannabinol >10000 <0.2%
Δ9-Tetrahydrocannabinol >10000 <0.2%
Cannabinol >10000 <0.2%
To evaluate potential positive or negative interference, non-structurally related compounds
were added to drug-free urine and to urine samples containing the claimed analytes at 25%
below and 25% above each corresponding cutoff.
Potential interferents were spiked in at a concentration of 100 μg/mL except for albumin at
100 mg/dL and ethanol at 1%.
The following compounds did not cause any positive or negative interference with any of the
16 assays with the candidate device.
Acetaminophen, Acetophenetidin, N-Acetylprocainamide, Acetylsalicylic acid, Albumin
(100mg/dL), Aminopyrine, Amoxicillin, Ampicillin, Apomorphine, Ascorbic acid,
Aspartame, Atropine, Benzilic acid, Benzoic acid, Bilirubin, Chloral hydrate, Digoxin,
Diphenhydramine, Ecgonine methyl ester, β-Estradiol, Erythromycin, Ethanol (1%),
Fenoprofen, Furosemide, Gentisic acid, Hemoglobin, Hydralazine, Hydrochlorothiazide,
Hydrocortisone, O-Hydroxyhippuric acid, 3-Hydroxytyramine, Ibuprofen, Isoproterenol,
Isoxsuprine, Ketamine, Ketoprofen, Labetalol, Loperamide, Meperidine, Meprobamate,
Methoxyphenamine, Nalidixic acid, Naloxone, Naltrexone, Naproxen, Niacinamide,
Nifedipine, Norethindrone, Noscapine, (±)-Octopamine, Oxalic acid, Oxolinic acid,
Oxymetazoline, Papaverine, Penicillin G, Perphenazine, Phenelzine, Prednisone, (±)-
Propranolol, Pseudoephedrine, Quinine, Ranitidine, Salicylic acid, Serotonin (5-
Hydroxytyramine), Sulfamethazine Sulindac, Tetrahydrocortisone, 3-(β-D glucuronide,
Tetrahydrocortisone 3-acetate, Tetrahydrozoline, Thiamine, Thioridazine, Triamterene,
Trifluoperazine, Trimethoprim, DL-Tryptophan, Tyramine, DL-Tyrosine, Uric acid,
Verapamil, and Zomepirac.
The sponsor also performed studies to evaluate the effect of urine pH and specific gravity on
the results. Samples with concentrations of 0 (drug-free), at 25% below and 25% above
each corresponding cutoff were adjusted to pH levels of 4, 5, 6, 7, 8, and 9 and at a specific
gravity of 1.001, 1.003, 1.005, 1.007, 1.009, 1.010, 1.012, 1.014, 1.015, 1.016, 1.017, 1.020,
1.021, 1.024, 1.025, 1.026, 1.027, 1.029, and 1.030.

[Table 1 on page 13]
6-acetylmorphine
(Cut-off=10 ng/mL)	Result
Positive at (ng/mL)	% Cross-Reactivity
Oxymorphone-3β-D-
glucuronide	>100,000	<0.01%
Tapentadol HCl	>100,000	<0.01%
Tramadol	>100,000	<0.01%

[Table 2 on page 13]
Marijuana
(Cut-off=20 ng/mL)	Result
Positive at
(ng/mL)	% Cross-
Reactivity
11-nor-D9-THC-9 COOH	20	100%
11-nor-D8-THC-9 COOH	20	100%
Δ8-Tetrahydrocannabinol	>10000	<0.2%
Δ9-Tetrahydrocannabinol	>10000	<0.2%
Cannabinol	>10000	<0.2%

--- Page 14 ---
There were no deviations from the expected negative or positive results for either pH or
specific gravity.
4. Assay Reportable Range:
Not applicable.
5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods):
The sponsor’s stability protocols were reviewed and found to be acceptable. A shelf-life
stability of 24 months from the date of manufacture is claimed.
6. Detection Limit:
Not applicable.
7. Assay Cut-Off:
See section VII.A.1 above for a description of how the device performs around the cutoffs.
B Comparison Studies:
1. Method Comparison with Predicate Device:
Method comparison studies for the AssureTech DOA Dipstick Screen Panel Tests and the
AssureTech DOA Integrated Cup Tests were performed in-house with three laboratory
assistants for each device. Operators ran 80 (40 negative and 40 positive) unaltered clinical
samples for each drug. The samples were blind labeled and compared to GC/MS results. The
results are presented in the tables below for 6-MAM and THC. Please refer to k181768 for
the method comparison performance for the remaining assays.
Near Cutoff Near Cutoff
Low Negative Negative by Positive by High Positive
Dip
by LC/MS LC/MS LC/MS by LC/MS
Negative
(less than (Between (Between the (greater than
6-MAM
-50%) -50% and cutoff and +50%)
cutoff) +50%)
Viewer Positive 0 0 0 15 5
1 Negative 10 20 10 0 0
Viewer Positive 0 0 0 15 25
2 Negative 10 20 10 0 0
Viewer Positive 0 0 0 15 25
3 Negative 10 20 10 0 0

[Table 1 on page 14]
Dip
6-MAM		Negative	Low Negative
by LC/MS
(less than
-50%)	Near Cutoff
Negative by
LC/MS
(Between
-50% and
cutoff)	Near Cutoff
Positive by
LC/MS
(Between the
cutoff and
+50%)	High Positive
by LC/MS
(greater than
+50%)
Viewer
1	Positive	0	0	0	15	5
	Negative	10	20	10	0	0
Viewer
2	Positive	0	0	0	15	25
	Negative	10	20	10	0	0
Viewer
3	Positive	0	0	0	15	25
	Negative	10	20	10	0	0

--- Page 15 ---
Near Cutoff Near Cutoff
Low Negative Negative by Positive by High Positive
Cup
by LC/MS LC/MS LC/MS by LC/MS
Negative
(less than (Between (Between the (greater than
6-MAM
-50%) -50% and cutoff and +50%)
cutoff) +50%)
Viewer Positive 0 0 0 15 25
1 Negative 10 20 10 0 0
Positive 0 0 0 15 25
Viewer
Negative 10 20 10 0 0
2
Viewer Positive 0 0 0 15 25
3 Negative 10 20 10 0 0
Near Cutoff Near Cutoff
High
Low Negative Negative by Positive by
Dip Positive by
by LC/MS LC/MS LC/MS
Negative LC/MS
(less than (Between (Between the
THC (greater than
-50%) -50% and cutoff and
+50%)
cutoff) +50%)
Viewer Positive 0 0 0 14 25
1 Negative 10 20 10 1 0
Positive 0 0 1 15 25
Viewer
Negative 10 20 9 0 0
2
Viewer Positive 0 0 1 15 25
3 Negative 10 20 9 0 0
Near Cutoff Near Cutoff
High
Low Negative Negative by Positive by
Cup Positive by
by LC/MS LC/MS LC/MS
Negative LC/MS
(less than (Between (Between the
THC (greater than
-50%) -50% and cutoff and
+50%)
cutoff) +50%)
Viewer Positive 0 0 0 14 25
1 Negative 10 20 10 1 0
Positive 0 0 0 15 25
Viewer
Negative 10 20 10 0 0
2
Viewer Positive 0 0 1 15 25
3 Negative 10 20 9 0 0

[Table 1 on page 15]
Cup
6-MAM		Negative	Low Negative
by LC/MS
(less than
-50%)	Near Cutoff
Negative by
LC/MS
(Between
-50% and
cutoff)	Near Cutoff
Positive by
LC/MS
(Between the
cutoff and
+50%)	High Positive
by LC/MS
(greater than
+50%)
Viewer
1	Positive	0	0	0	15	25
	Negative	10	20	10	0	0
Viewer
2	Positive	0	0	0	15	25
	Negative	10	20	10	0	0
Viewer
3	Positive	0	0	0	15	25
	Negative	10	20	10	0	0

[Table 2 on page 15]
Dip
THC		Negative	Low Negative
by LC/MS
(less than
-50%)	Near Cutoff
Negative by
LC/MS
(Between
-50% and
cutoff)	Near Cutoff
Positive by
LC/MS
(Between the
cutoff and
+50%)	High
Positive by
LC/MS
(greater than
+50%)
Viewer
1	Positive	0	0	0	14	25
	Negative	10	20	10	1	0
Viewer
2	Positive	0	0	1	15	25
	Negative	10	20	9	0	0
Viewer
3	Positive	0	0	1	15	25
	Negative	10	20	9	0	0

[Table 3 on page 15]
Cup
THC		Negative	Low Negative
by LC/MS
(less than
-50%)	Near Cutoff
Negative by
LC/MS
(Between
-50% and
cutoff)	Near Cutoff
Positive by
LC/MS
(Between the
cutoff and
+50%)	High
Positive by
LC/MS
(greater than
+50%)
Viewer
1	Positive	0	0	0	14	25
	Negative	10	20	10	1	0
Viewer
2	Positive	0	0	0	15	25
	Negative	10	20	10	0	0
Viewer
3	Positive	0	0	1	15	25
	Negative	10	20	9	0	0

--- Page 16 ---
2. Matrix Comparison:
Not applicable. The assays are only intended for use with urine samples.
C Clinical Studies:
1. Clinical Sensitivity:
Not applicable.
2. Clinical Specificity:
Not applicable.
3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):
Not applicable.
D Clinical Cut-Off:
Not applicable.
E Expected Values/Reference Range:
Not applicable.
VIII Proposed Labeling:
The labeling supports the finding of substantial equivalence for this device.
IX Conclusion:
The submitted information in this premarket notification is complete and supports a substantial
equivalence decision.